Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Benjamin Albert submitted a Form 144 reporting an intended sale of restricted common stock of Health Catalyst, Inc. on 03/02/2026. The filing lists 4,966 shares in connection with broker Morgan Stanley Smith Barney LLC and shows a prior sale of 13,304 shares on 02/26/2026.
Health Catalyst, Inc. (restricted shares reported for sale)
The filing reports a proposed resale of 25,795 restricted shares to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026. The filing also documents prior restricted-share dispositions by Daniel Burton: 55,715 shares on 12/01/2025 and 28,875 shares on 02/26/2026. Shares outstanding were 70,730,884 as of 03/02/2026.
Health Catalyst, Inc. filed a Form 144 reporting 13,836 common shares to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026, listed as restricted stock issued for compensation. The filing shows earlier dispositions by Linda Llewelyn of 9,762 shares on 12/01/2025 and 4,471 shares on 02/26/2026 with aggregate amounts of $28,311.75 and $7,814.41 respectively. Shares outstanding were reported as 70,730,884 as of 03/02/2026.
Health Catalyst, Inc. filed a Form 144 registering 20,838 shares of common stock for sale on 03/02/2026.
The filing identifies the broker Morgan Stanley Smith Barney LLC and lists the securities as restricted stock issued as compensation. The excerpt also reports prior restricted‑stock sales by Benjamin Landry of 14,387 shares on 12/01/2025, 27,425 shares on 12/05/2025, and 6,317 shares on 02/26/2026.
Health Catalyst, Inc. reported a Form 144 notice for the proposed sale of 15,726 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026.
The filing also discloses recent insider sales by Kevin Freeman: 16,401 shares sold on 12/01/2025 for $47,566.18 and 6,614 shares sold on 02/26/2026 for $11,559.95.
Health Catalyst, Inc. CEO Albert Benjamin reported equity compensation and a related tax-withholding share sale. On February 25, 2026, he received 930,000 restricted stock units (RSUs) and 38,833 performance-based RSUs (PRSUs), each convertible into one common share if vesting conditions are met.
Under the company’s 2019 Stock Option and Incentive Plan, 16.67% of the RSUs vest on March 1, 2026, with the remaining 83.33% vesting in 10 equal quarterly installments. The PRSUs were granted based on performance criteria for the fiscal year ended December 31, 2025.
On February 26, 2026, Benjamin disposed of 13,304 common shares at $1.7478 per share to satisfy tax withholding obligations from vested RSUs. The company describes this as a mandatory "sell to cover" transaction rather than a discretionary trade.
Health Catalyst, Inc. Chief People Officer Linda Llewelyn reported equity compensation and related tax withholding transactions in company common stock. She received a grant of 191,500 restricted stock units (RSUs), each representing one share, which will vest in 12 equal quarterly installments beginning on March 1, 2026.
She was also credited with 13,195 performance-based restricted stock units (PRSUs) tied to the company’s performance for the fiscal year ended December 31, 2025. Separately, 4,471 shares were disposed of at $1.7478 per share to cover tax withholding obligations in connection with RSU vesting, under a mandated "sell to cover" election, and not as a discretionary trade. After these transactions, she directly owned 343,487 shares of common stock.
Health Catalyst, Inc. General Counsel Benjamin Landry reported stock-based compensation and a related tax sale of common stock. On February 25, 2026, he received an award of 289,000 restricted stock units (RSUs) that will vest in 12 equal quarterly installments beginning on March 1, 2026, each RSU converting into one share of common stock when vested.
He was also granted 16,473 performance-based restricted stock units (PRSUs) tied to performance criteria for the fiscal year ended December 31, 2025. On February 26, 2026, 6,317 shares were disposed of at $1.7478 per share to cover tax withholding obligations from vesting RSUs, a mandated “sell-to-cover” under the company’s equity plans rather than a discretionary trade. After these transactions, he directly owned 399,156 shares of common stock.
Health Catalyst, Inc. Chief Financial Officer Jason Alger reported equity compensation awards and an automatic tax-related share sale. On February 25, 2026, he received 507,500 restricted stock units (RSUs) and 22,222 performance-based RSUs under the company’s 2019 Stock Option and Incentive Plan.
Each RSU and PRSU represents a right to receive one share of common stock, with the RSUs vesting in 12 equal quarterly installments beginning on March 1, 2026 and the PRSUs tied to performance for the fiscal year ended December 31, 2025. On February 26, 2026, 7,522 shares were disposed of at $1.7478 per share solely to cover tax withholding obligations in a mandatory “sell to cover” transaction, which the filing states was not a discretionary trade by Alger. Following these transactions, he held 768,614 shares of common stock directly.
Health Catalyst, Inc. Form 144 reports a proposed sale of 6,317 restricted common shares and discloses recent restricted-stock dispositions by Benjamin Landry of 14,387 and 27,425 shares. The filing names Morgan Stanley Smith Barney LLC as the broker and lists 02/26/2026 as the sale date for the planned transaction.